by GlyTherix | Jul 21, 2022
Date, July 21 2022: Sydney. GlyTherix is pleased to announce the successful completion of its high-yield GMP-grade stable cell line development program for its proprietary antibody Miltuximab® in partnership with international biologics manufacturer GenScript ProBio...
by GlyTherix | Jul 8, 2022
Date, July 8 2022: Sydney. GlyTherix has commenced an exciting new collaboration with the GastroEsophageal Malignancies Investigator Network Initiative (GEMINI) to test its Miltuximab® monoclonal antibody therapies in gastroesophageal cancers. GEMINI, backed by the...
by GlyTherix | Dec 1, 2021
GlyTherix is pleased to announce the award of a $50,000 COVID-19 TechVoucher by the NSW Government through Investment NSW that will provide funding support to collaborate with ANSTO’s world-leading radiochemistry and preclinical imaging teams. Funds will be used to...
by GlyTherix | Mar 3, 2021
GlyTherix Ltd is proud to be a recipient of the first round of the Pipeline Accelerator 2020-21 scheme from Therapeutic Innovation Australia (TIA). Round 1 saw the award of $685,000 to 21 projects. Our project “Optimisation and characterisation of Miltuximab®-DFO...
by GlyTherix | Sep 10, 2020
PRESS RELEASE September 10, 2020 Adelaide, Australia and Sydney, Australia. CAR-T biotherapeutics company Carina Biotech and immuno-oncology company GlyTherix are pleased to announce a co-development agreement that could result in a promising new CAR-T therapy that is...
by GlyTherix | May 19, 2020
Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...
